

## Supplementary Online Content

Haaland GS, Falk RS, Straume O, Lorens JB. Association of warfarin use with lower overall cancer incidence among patients older than 50 years. *JAMA Intern Med*. Published online November 6, 2017. doi:10.1001/jamainternmed.2017.5512

**eTable 1.** Number of Cases and Incidence Rate Ratio of Cancer in Warfarin Users Compared to Non-Users

**eTable 2.** Sensitivity Analyses

**eTable 3.** Number of Cases and Incidence Rate Ratio of Cancer in Warfarin Users After Atrial Fibrillation/Flutter Compared to Non-Users

This supplementary material has been provided by the authors to give readers additional information about their work.

**eTable 1.** Number of Cases and Incidence Rate Ratio of Cancer in Warfarin Users Compared to Non-Users

<b>Cancer site</b>	<b>IRR</b>	<b>95% CI</b>	<b>Non-users (cancer cases)</b>	<b>Warfarin users (cancer cases)</b>
<b>All cancers</b>	0.84	0.82-0.86	123933	8754
<b>Prostate</b>	0.69	0.65-0.72	24218	1699
<b>Lung</b>	0.80	0.75-0.86	13644	932
<b>NSCLC</b>	0.80	0.74-0.87	9477	622
<b>SCLC</b>	0.71	0.59-0.86	2131	121
<b>Colon</b>	0.99	0.93-1.06	12173	1100
<b>Breast</b>	0.90	0.82-1.00	11566	415
<b>Ductal</b>	0.90	0.81-1.02	8937	312
<b>Lobular</b>	1.00	0.75-1.32	1332	54
<b>Skin<sup>a</sup></b>	1.09	1.01-1.18	5833	712
<b>Gynecological</b>	0.85	0.74-0.97	5973	241
<b>Ovary</b>	0.81	0.65-1.02	2057	78
<b>Uterus</b>	0.91	0.77-1.08	3492	146
<b>Cervix</b>	1.03	0.69-1.54	620	26
<b>Vulva and vagina</b>	0.64	0.39-1.04	424	17
<b>Bone marrow</b>	1.00	0.91-1.10	5672	502
<b>Leukemia</b>	0.99	0.89-1.11	4394	326
<b>CLL</b>	0.89	0.71-1.11	1204	87
<b>AML</b>	0.70	0.51-0.98	623	41
<b>Bladder</b>	0.82	0.75-0.90	5559	491
<b>Malignant melanoma</b>	0.96	0.87-1.07	5625	389
<b>Rectum and Anus</b>	0.77	0.69-0.86	5179	336
<b>Rectum</b>	0.76	0.68-0.85	4928	323
<b>Anus</b>	0.90	0.51-1.58	251	13
<b>Lymphoma</b>	0.92	0.82-1.04	4182	299
<b>Hodkins</b>	0.66	0.34-1.26	215	10
<b>Non-Hodkins</b>	0.92	0.81-1.04	3569	252
<b>Brain</b>	0.74	0.64-0.87	3631	173
<b>Astrocytoma</b>	0.75	0.57-0.98	1076	55
<b>Meningioma</b>	0.66	0.51-0.86	1567	61
<b>Glioblastoma</b>	0.75	0.56-1.00	955	50
<b>Kidney and ureters</b>	0.93	0.82-1.06	3489	270
<b>Kidney</b>	0.96	0.84-1.10	2912	224
<b>Pancreas</b>	0.92	0.80-1.04	3245	262
<b>Stomach</b>	0.77	0.65-0.90	2171	165
<b>Head and neck</b>	0.64	0.51-0.81	1698	78
<b>Tongue</b>	0.30	0.16-0.56	435	10
<b>Throat</b>	0.59	0.39-0.90	612	22
<b>Larynx</b>	0.75	0.55-1.04	589	40
<b>Salivary gland</b>	1.34	0.74-2.41	133	13

**eTable 1. (Continued)** Number of Cases and Incidence Rate Ratio of Cancer in Warfarin Users Compared to Non-Users

<b>Cancer site</b>	<b>IRR</b>	<b>95% CI</b>	<b>Non-users (cancer cases)</b>	<b>Warfarin users (cancer cases)</b>
<b>Mouth</b>	0.80	0.56-1.14	518	33
<b>Esophagus</b>	1.03	0.83-1.27	1013	94
<b>Gallbladder</b>	0.94	0.71-1.24	716	56
<b>Endocrine glands<sup>b</sup></b>	0.53	0.36-0.80	689	25
<b>Thyroid</b>	0.81	0.56-1.18	640	29
<b>Small intestine</b>	0.85	0.62-1.19	582	39
<b>Liver</b>	0.67	0.51-0.92	468	50
<b>Lip</b>	0.83	0.59-1.18	483	37
<b>Pleura</b>	0.65	0.44-0.95	446	28
<b>Soft tissue</b>	0.55	0.31-0.97	313	13
<b>Peritoneum</b>	0.53	0.28-1.00	311	10
<b>Eye</b>	0.63	0.34-1.17	248	11
<b>Penis</b>	0.96	0.59-1.54	193	20
<b>Nose</b>	0.94	0.55-1.62	187	14
<p><b>Abbreviations: IRR, Incidence rate ratio (adjusted for sex and age); CI, Confidence Interval NSCLC, Non-small cell lung cancer; SCLC, Small cell lung cancer; CLL, Chronic lymphatic leukemia AML, Acute myeloid leukemia</b>  <sup>a</sup> excluding malignant melanoma and basal cell carcinoma  <sup>b</sup> excluding thyroid  <b>Number warfarin users: 92,942 Person-years warfarin users: 430,266</b>  <b>Number non-users 1,163,783 Person-years non-users: 7,577,952</b></p>				

**eTable 2.** Sensitivity Analyses

<b>Analyses all cancers</b>	<b>All warfarin users</b>	
	<b>IRR</b>	<b>95 % CI</b>
Age-groups		
52-62	0.87	0.82-0.93
63-72	0.87	0.84-0.91
73-82	0.82	0.79-0.84
Gender		
Male	0.82	0.80-0.84
Female	0.89	0.86-0.93
Duration of use		
6-12 months	0.58	0.51-0.64
12-36 months	0.89	0.84-0.94
36-60 months	1.07	1.02-1.12
60-96 months	0.90	0.87-0.94
>96 months	0.69	0.66-0.72
User definition		
Interval prescription - cancer		
6 months interval	1.06	1.04-1.08
1 year interval	1.00	0.98-1.02
1,5 years interval	0.93	0.91-0.95
2 years interval (as used in study)	0.84	0.82-0.86
2,5 years interval	0.78	0.77-0.80
3 years interval	0.72	0.71-0.74
New user design		
	0.71	0.67-0.77
<b>Competing risk regression with death as competing risk</b>	<b>SHR</b>	<b>95% CI</b>
	0.85	0.79-0.91
Abbreviations: IRR, Incidence rate ratio (adjusted for sex and age), SHR subdistribution hazard ratio, CI, Confidence Interval		

**eTable 3.** Number of Cases and Incidence Rate Ratio of Cancer in Warfarin Users After Atrial Fibrillation/Flutter Compared to Non-Users

<b>Cancer site</b>	<b>IRR</b>	<b>95% CI</b>	<b>Non-users (cancer cases)</b>	<b>Warfarin users after AF (cancer cases)</b>
<b>All cancers</b>	0.62	0.59-0.65	123933	2058
<b>Prostate</b>	0.60	0.55-0.66	24218	470
<b>Lung</b>	0.39	0.33-0.46	13644	147
<b>Colon</b>	0.71	0.63-0.81	12173	256
<b>Breast</b>	0.72	0.59-0.87	11566	107
<b>Skin<sup>a</sup></b>	0.87	0.75-1.01	6545	183
<b>Gynecological</b>	0.67	0.52-0.86	5973	63
<b>Bone marrow</b>	0.66	0.55-0.80	5672	107
<b>Bladder</b>	0.64	0.54-0.77	5559	122
<b>Malignant melanoma</b>	0.92	0.76-1.11	5625	118
<b>Rectum and anus</b>	0.51	0.40-0.64	5179	71
<b>Lymphoma</b>	0.74	0.59-0.93	4182	77
<b>Brain</b>	0.53	0.38-0.72	3631	39
<b>Kidney and ureters</b>	0.60	0.46-0.78	3489	56
<b>Pancreas</b>	0.54	0.41-0.72	3245	50
<b>Stomach</b>	0.51	0.36-0.71	2171	35
<b>Head and neck</b>	0.52	0.33-0.80	1698	20
<b>Esophagus</b>	0.51	0.31-0.86	1013	15
<b>Thyroid</b>	1.06	0.60-1.88	640	12
<b>Abbreviations: IRR, Incidence rate ratio (adjusted for sex and age), CI, Confidence Interval AF, Atrial fibrillation/flutter</b> <sup>a</sup> <b>excluding malignant melanoma and basal cell carcinoma</b> <b>Number warfarin users: 92,942 Person-years warfarin users: 135,617</b> <b>Number non-users 1,163,783 Person-years non-users: 7,577,952</b>				